Abstracts tagged "renal disease and glomerulonephritis"

Abstract Number: 2786 • 2019 ACR/ARP Annual Meeting
Renal Histopathological Classifications Predict the Renal Outcomes of Plasma Exchange-Treated ANCA-Associated Vasculitides with Renal Failure
Dorian Nezam ¹, Pauline Morel ¹, Stanislas Faguer ², Alexandre Karras ³, Julien Aniort ⁴, Dimitri Titeca-Beauport ⁵, Justine Solignac ⁶, Didier Ducloux ⁷, Rafik Mesbah ⁸, Pierre-Louis Carron ⁹, Cédric Rafat ¹⁰, Pierre Gobert ¹¹, Vincent Audard ¹², Séverine Beaudreuil ¹³, François Maurier ¹⁴, Nihal Martis ¹⁵, Aurélien Tiple ⁴, Stéphane Bally ¹⁶, Aurélie Hummel ¹⁷, Claire de Moreuil ¹⁸, Tiphaine Goulenok ¹⁷, Dominique Nochy ¹⁹, Noémie Jourde-Chiche ²⁰, Alexis Régent ²¹, Loic Guillevin ²¹ and Benjamin Terrier²¹, ¹Cochin Hospital, Paris, France, ²CHU Toulouse, Toulouse, France, ³Paris HEGP, Paris, France, ⁴CHU, Clermont-Ferrand, France, ⁵CHU, Amiens, France, ⁶CHU, Marseille, France, ⁷CHU, Besancon, France, ⁸CH, Boulogne sur Mer, France, ⁹Grenoble, Grenoble, France, ¹⁰Tenon Hospital, Paris, France, ¹¹Clinique Rhone Durance, Avignon, France, ¹²Henri Mondor Hospital, Créteil, France, ¹³Bicetre Hospital, Le Kremlin Bicetre, France, ¹⁴Service de Médecine Interne, Hôpital Belle Isle, Metz, Metz, France, ¹⁵CHU, Nice, France, ¹⁶CH, Chambery, France, ¹⁷APHP, Paris, France, ¹⁸CHU Brest, Brest, France, ¹⁹HEGP Hospital, Paris, France, ²⁰APHM, Marseille, Marseille, France, ²¹National Referral Center for Rare Systemic Autoimmune Diseases Paris Cochin, Paris, France
Background/Purpose: ANCA-associated vasculitides (AAVs) are the most frequent cause of rapidly progressive glomerulonephritis (RPGN), for which the major prognostic issue is the risk of developing…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].